Total Payments
$2,143
2024 Payments
$146.72
Companies
21
Transactions
61
Medicare Patients
4,598
Medicare Billing
$813,168
Payment Breakdown by Category
Food & Beverage$1,796 (83.8%)
Education$346.98 (16.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,796 | 57 | 83.8% |
| Education | $346.98 | 4 | 16.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $432.19 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $336.98 | 7 | $0 (2024) |
| Allergan, Inc. | $269.38 | 5 | $0 (2019) |
| Melinta Therapeutics, LLC | $221.65 | 9 | $0 (2024) |
| The Medicines Company | $215.39 | 10 | $0 (2017) |
| Medtronic Vascular, Inc. | $125.00 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $124.73 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $85.00 | 1 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $58.04 | 3 | $0 (2017) |
| Shionogi Inc | $47.98 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $146.72 | 5 | Astellas Pharma US Inc ($34.52) |
| 2023 | $105.73 | 4 | Melinta Therapeutics, LLC ($57.75) |
| 2022 | $44.16 | 2 | Melinta Therapeutics, LLC ($22.42) |
| 2021 | $53.06 | 2 | AbbVie Inc. ($28.29) |
| 2020 | $103.60 | 2 | Janssen Biotech, Inc. ($85.00) |
| 2019 | $249.36 | 2 | Gilead Sciences, Inc. ($124.73) |
| 2018 | $584.34 | 13 | Astellas Pharma US Inc ($219.58) |
| 2017 | $856.44 | 31 | The Medicines Company ($215.39) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $34.52 | General |
| Category: Infectious Diseases | ||||||
| 10/29/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: ANTIBIOTIC | ||||||
| 03/27/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: ANTIFUNGALS | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: Oncology | ||||||
| 01/30/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/25/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $34.13 | General |
| Category: ANTIFUNGALS | ||||||
| 09/26/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/28/2023 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Rezzayo, Vabomere | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: ANTIBIOTICS | ||||||
| 05/24/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/09/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.74 | General |
| Category: Hematology | ||||||
| 03/09/2022 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Vabomere | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: ANTIBIOTICS | ||||||
| 11/10/2021 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Vabomere | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: ANTIBIOTICS | ||||||
| 05/19/2021 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/21/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/13/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $85.00 | General |
| Category: Oncology | ||||||
| 12/16/2019 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $124.73 | General |
| Category: HIV | ||||||
| 03/26/2019 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $124.63 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/25/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 06/19/2018 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/23/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 03/27/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $74.99 | General |
| 03/19/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 03/19/2018 | Astellas Pharma US Inc | MYCAMINE (Drug), CRESEMBA | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 03/13/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug), Orbactiv, MINOCIN | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 03/01/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $124.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 992 | 2,540 | $679,425 | $178,552 |
| 2022 | 5 | 1,085 | 2,957 | $799,900 | $196,832 |
| 2021 | 6 | 1,206 | 3,052 | $810,645 | $205,004 |
| 2020 | 5 | 1,315 | 3,455 | $914,950 | $232,780 |
Total Patients
4,598
Total Services
12,004
Medicare Billing
$813,168
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 483 | 1,837 | $459,250 | $113,233 | 24.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 234 | 379 | $132,650 | $34,785 | 26.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 183 | 191 | $52,575 | $19,518 | 37.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 59 | 60 | $24,000 | $8,161 | 34.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 33 | 73 | $10,950 | $2,856 | 26.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 528 | 2,127 | $531,750 | $120,750 | 22.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 263 | 494 | $172,900 | $40,449 | 23.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 183 | 187 | $51,450 | $20,059 | 39.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 86 | 86 | $34,350 | $13,596 | 39.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 25 | 63 | $9,450 | $1,978 | 20.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 570 | 2,176 | $544,000 | $125,455 | 23.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 265 | 428 | $149,800 | $35,714 | 23.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 231 | 244 | $67,175 | $26,602 | 39.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 79 | 79 | $31,550 | $12,780 | 40.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 45 | 104 | $15,600 | $3,179 | 20.4% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 16 | 21 | $2,520 | $1,273 | 50.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 683 | 2,605 | $651,250 | $153,997 | 23.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 285 | 441 | $154,350 | $37,292 | 24.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 207 | 212 | $58,300 | $23,737 | 40.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 84 | 86 | $34,400 | $14,180 | 41.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 56 | 111 | $16,650 | $3,574 | 21.5% |
About Dr. Joseph Katta, DO
Dr. Joseph Katta, DO is a Infectious Disease healthcare provider based in Altamonte Springs, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1518120708.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Katta, DO has received a total of $2,143 in payments from pharmaceutical and medical device companies, with $146.72 received in 2024. These payments were reported across 61 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,796).
As a Medicare-enrolled provider, Katta has provided services to 4,598 Medicare beneficiaries, totaling 12,004 services with total Medicare billing of $813,168. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Altamonte Springs, FL
- Active Since 07/08/2008
- Last Updated 07/09/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1518120708
Products in Payments
- ZERBAXA (Drug) $289.13
- AVYCAZ (Drug) $238.41
- ORBACTIV (Drug) $187.93
- TYRX (Device) $125.00
- Biktarvy (Drug) $124.73
- Cresemba (Drug) $124.62
- IMBRUVICA (Drug) $85.00
- Kimyrsa (Drug) $70.81
- Rezzayo (Drug) $59.00
- Fetroja (Drug) $47.98
- Baxdela (Drug) $47.13
- TEFLARO (Drug) $46.98
- Vabomere (Drug) $44.71
- RELISTOR (Drug) $38.07
- SYNDROS (Drug) $36.84
- DIFICID (Drug) $32.86
- TUKYSA (Drug) $29.88
- VABOMERE (Drug) $27.46
- NUZYRA (Drug) $24.59
- MYCAMINE (Drug) $23.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Altamonte Springs
Dr. Juan Diaz, D.o, D.O
Infectious Disease — Payments: $1.1M
Infectious Disease $1.1M
Jason Sniffen, Do, DO
Infectious Disease — Payments: $459,299
Infectious Disease $459,299
Christopher Cooper, Md, MD
Infectious Disease — Payments: $373,256
Infectious Disease $373,256
Fernando Alvarado, Md, MD
Infectious Disease — Payments: $16,125
Infectious Disease $16,125
Javier Marinez, Md, MD
Infectious Disease — Payments: $7,961
Infectious Disease $7,961
Dr. Anibal Maldonado, M.d, M.D
Infectious Disease — Payments: $4,049
Infectious Disease $4,049